4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on ...
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market ...
Non-Muscle Invasive Bladder Cancer Market Set to Reach New Heights Amidst Growing Pipeline and Research Initiatives | DelveInsight
Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's ...
TMCnet5d
EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment
BioCina's Chief Executive Officer, Mark W. Womack stated, "I'm so very proud for BioCina to be entrusted to advance ...
Hosted on MSN6mon
More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’
Investors got a good case of whiplash over the past four years. The pandemic crash of 2020 brought a decade-long bull market to a screeching halt. However, the spin-up into the revenge-buying bull ...
CereVasc Announces Journal of Molecular Therapy Publication Highlighting the eShunt® Platform as a CNS Gene Therapy Delivery Method
CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today ...
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic ...